ReviewFrontiers in neuroscience2015
Brain "fog," inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin.
Review in Frontiers in neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 153 citations in OpenAlex.
- Genetics of COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome: a systematic review.Annals of clinical and translational neurology · 2022Pooled it
- Mast cells in meningiomas and brain inflammation.Journal of neuroinflammation · 2015Pooled it
- Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary Analysis.Advances in therapy · 2024Trial
- Neuroimmune Regulation of Microvascular Inflammation: The Heart-Brain Axis, Mast Cells, and the Protective Role of Flavonoids-A Comprehensive Review.Biomedicines · 2026Review
- Long COVID-associated neurological symptoms and brain fog: Understanding the mechanism of neuroinflammation, BBB disruption, diagnostics, and therapeutics.Molecular biology reports · 2026Review
- Is histamine intolerance a treatable subtype of fibromyalgia? evidence and clinical implications-narrative review.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
- New Characterization of Lipedema Stages: Focus on Pain, Water, Fat and Skeletal Muscle.Life (Basel, Switzerland) · 2025Article
- How Are Brain Fog Symptoms Related to Diet, Sleep, Mood and Gastrointestinal Health? A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2025Article
- Review
- Therapeutic Expedition of Luteolin against Brain-related Disorders: An Updated Review.Combinatorial chemistry & high throughput screening · 2025Review
- Brain Fog: a Narrative Review of the Most Common Mysterious Cognitive Disorder in COVID-19.Molecular neurobiology · 2024Review
- Psychiatric adverse events following COVID-19 vaccination: a population-based cohort study in Seoul, South Korea.Molecular psychiatry · 2024Article
- Development of the Sensory-Motor Dysfunction Questionnaire and Pilot Reliability Testing.Brain sciences · 2024Article
- Mast Cells in Autism Spectrum Disorder-The Enigma to Be Solved?International journal of molecular sciences · 2024Review
- A multiscale inflammatory map: linking individual stress to societal dysfunction.Frontiers in science · 2024Article
- The neurobiology of SARS-CoV-2 infection.Nature reviews. Neuroscience · 2024Review
- Cognitive, neuropsychiatric and neurological alterations in mastocytosis: A systematic review.Clinical and translational allergy · 2023Review
- Serum ferritin level during hospitalization is associated with Brain Fog after COVID-19.Scientific reports · 2023Article
- Potential Role of Moesin in Regulating Mast Cell Secretion.International journal of molecular sciences · 2023Review
- Mast Cell Activation Syndrome Update-A Dermatological Perspective.Journal of personalized medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Brain "fog" is a constellation of symptoms that include reduced cognition, inability to concentrate and multitask, as well as loss of short and long term memory. Brain "fog" characterizes patients with autism spectrum disorders (ASDs), celiac disease, chronic fatigue syndrome, fibromyalgia, mastocytosis, and postural tachycardia syndrome (POTS), as well as "minimal cognitive impairment," an early clinical presentation of Alzheimer's disease (AD), and other neuropsychiatric disorders. Brain "fog" may be due to inflammatory molecules, including adipocytokines and histamine released from mast cells (MCs) further stimulating microglia activation, and causing focal brain inflammation. Recent reviews have described the potential use of natural flavonoids for the treatment of neuropsychiatric and neurodegenerative diseases. The flavone luteolin has numerous useful actions that include: anti-oxidant, anti-inflammatory, microglia inhibition, neuroprotection, and memory increase. A liposomal luteolin formulation in olive fruit extract improved attention in children with ASDs and brain "fog" in mastocytosis patients. Methylated luteolin analogs with increased activity and better bioavailability could be developed into effective treatments for neuropsychiatric disorders and brain "fog."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.